NASDAQ:ATRSAntares Pharma Stock Price, Forecast & News

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRS stock has increased by 4.0% and is now trading at $3.12. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Strong Buy." View analyst ratings for Antares Pharma.

Antares Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Antares Pharma.

Antares Pharma Inc (NASDAQ:ATRS) issued its quarterly earnings data on Tuesday, May, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.00 by $0.01. The specialty pharmaceutical company had revenue of $33.08 million for the quarter, compared to analyst estimates of $30.50 million. Antares Pharma had a return on equity of 2.38% and a net margin of 0.86%. View Antares Pharma's earnings history.

2 Wall Street analysts have issued 1 year price targets for Antares Pharma's stock. Their forecasts range from $4.50 to $6.00. On average, they anticipate Antares Pharma's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price. View analysts' price targets for Antares Pharma.

News coverage about ATRS stock has been trending negative on Friday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Antares Pharma earned a news impact score of -2.6 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAntares Pharma.

Antares Pharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,330,000 shares, an increase of 13.4% from the April 30th total of 3,820,000 shares. Based on an average daily volume of 1,640,000 shares, the short-interest ratio is currently 2.6 days. Currently, 2.8% of the company's stock are sold short. View Antares Pharma's Current Options Chain.

Some companies that are related to Antares Pharma include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Meridian Bioscience (VIVO) and Anika Therapeutics (ANIK). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Conatus Pharmaceuticals (CNAT), Novavax (NVAX), NVIDIA (NVDA), Prospect Capital (PSEC), Enviva Partners (EVA), Hi-Crush Partners (HCLP), Macquarie Infrastructure (MIC) and Amarin (AMRN).

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Antares Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.85%), Sargent Investment Group LLC (2.78%), State Street Corp (2.35%), Geode Capital Management LLC (1.39%), Silvercrest Asset Management Group LLC (0.98%) and Two Sigma Advisers LP (0.95%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. View institutional ownership trends for Antares Pharma.

ATRS stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Two Sigma Investments LP, Parametric Portfolio Associates LLC, Morgan Stanley, Morgan Stanley, State Street Corp, Bank of New York Mellon Corp, and BlackRock Inc.. Company insiders that have sold Antares Pharma company stock in the last year include Marvin Samson, Robert F Apple, and Thomas J Garrity. View insider buying and selling activity for Antares Pharma.

ATRS stock was purchased by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., Oracle Investment Management Inc., Sargent Investment Group LLC, JPMorgan Chase & Co., GSA Capital Partners LLP, BNP Paribas Arbitrage SA, Healthcare Value Capital LLC, and Two Sigma Advisers LP. View insider buying and selling activity for Antares Pharma.

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ATRS stock can currently be purchased for approximately $3.12.

Antares Pharma has a market capitalization of $516.55 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.

The official website for Antares Pharma is www.antarespharma.com.

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]